BioSpace News Archive

Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its first quarter 2022 financial results on Thursday, May 12, 2022.

ResMed announced Brett Sandercock, chief financial officer, will present virtually at the Macquarie Australia Conference on Tuesday, May 3, 2022, beginning at approximately 8:45 a.m. via video webcast.

Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that four abstracts with clinical trial designs and clinical data of its innate cell engagers (ICE®) have been accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company’s first quarter 2022 financial results on Wednesday, May 4, 2022 after the close of U.S. financial markets.

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced positive topline results from a pharmacodynamic (“PD”) study for OPNT003, nasal nalmefene, (3mg nalmefene hydrochloride), an investigational treatment for opioid overdose.

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the first quarter 2022 after market close on Thursday, May 5, 2022.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that translational data for lifileucel in patients with metastatic melanoma will be highlighted at the upcoming 2022 ASCO Annual Meeting.

Myeloid Therapeutics, Inc., a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, announced that it will participate in one-on-one and small group meetings with investors at the Morgan Stanley Private Company Biotech Corporate Access Day.

BioMarin Pharmaceutical Inc. announced financial results for the first quarter ended March 31, 2022.

Surface Oncology announced that it will share a clinical update on SRF388 in an oral presentation at the American Society of Clinical Oncology 2022 Annual Meeting, to be held June 3-7, 2022 in Chicago, Il.